Free Trial

SciSparc (SPRC) Competitors

SciSparc logo
$6.91 -0.13 (-1.85%)
Closing price 03:59 PM Eastern
Extended Trading
$6.72 -0.19 (-2.68%)
As of 06:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SPRC vs. VIRX, BPTSY, VRPX, KRBP, NCNA, TFFP, MYMD, TCBP, BON, and VINC

Should you be buying SciSparc stock or one of its competitors? The main competitors of SciSparc include Viracta Therapeutics (VIRX), Biophytis (BPTSY), Virpax Pharmaceuticals (VRPX), Kiromic BioPharma (KRBP), NuCana (NCNA), TFF Pharmaceuticals (TFFP), MyMD Pharmaceuticals (MYMD), TC Biopharm (TCBP), Bon Natural Life (BON), and Vincerx Pharma (VINC). These companies are all part of the "pharmaceutical products" industry.

SciSparc vs. Its Competitors

SciSparc (NASDAQ:SPRC) and Viracta Therapeutics (NASDAQ:VIRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings, analyst recommendations and media sentiment.

25.1% of SciSparc shares are owned by institutional investors. Comparatively, 31.4% of Viracta Therapeutics shares are owned by institutional investors. 1.5% of SciSparc shares are owned by insiders. Comparatively, 10.7% of Viracta Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Viracta Therapeutics has a consensus price target of $1.75, indicating a potential upside of 12,862.96%. Given Viracta Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Viracta Therapeutics is more favorable than SciSparc.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SciSparc
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Viracta Therapeutics
0 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.33

SciSparc's return on equity of 0.00% beat Viracta Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
SciSparcN/A N/A N/A
Viracta Therapeutics N/A -1,899.61%-114.21%

In the previous week, SciSparc had 1 more articles in the media than Viracta Therapeutics. MarketBeat recorded 1 mentions for SciSparc and 0 mentions for Viracta Therapeutics. SciSparc's average media sentiment score of 0.00 equaled Viracta Therapeutics'average media sentiment score.

Company Overall Sentiment
SciSparc Neutral
Viracta Therapeutics Neutral

SciSparc has higher revenue and earnings than Viracta Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SciSparc$1.31M2.80-$6.28MN/AN/A
Viracta TherapeuticsN/AN/A-$51.06M-$1.10-0.01

SciSparc has a beta of 0.72, meaning that its share price is 28% less volatile than the S&P 500. Comparatively, Viracta Therapeutics has a beta of 1.06, meaning that its share price is 6% more volatile than the S&P 500.

Summary

Viracta Therapeutics beats SciSparc on 6 of the 11 factors compared between the two stocks.

Get SciSparc News Delivered to You Automatically

Sign up to receive the latest news and ratings for SPRC and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SPRC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SPRC vs. The Competition

MetricSciSparcMED IndustryMedical SectorNASDAQ Exchange
Market Cap$3.76M$2.43B$5.56B$9.04B
Dividend YieldN/A1.79%5.25%4.03%
P/E RatioN/A4.0519.5820.23
Price / Sales2.80765.58442.27127.79
Price / CashN/A164.1737.5058.41
Price / Book0.384.698.085.60
Net Income-$6.28M$31.26M$3.16B$248.43M
7 Day Performance1.25%6.81%3.77%5.15%
1 Month Performance-3.19%4.12%3.90%7.62%
1 Year Performance-51.02%4.05%34.22%21.56%

SciSparc Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SPRC
SciSparc
N/A$6.91
-1.8%
N/A-49.2%$3.76M$1.31M0.004
VIRX
Viracta Therapeutics
2.1483 of 5 stars
$0.02
-4.3%
$1.75
+11,190.3%
-97.1%$616KN/A-0.0120Gap Down
BPTSY
Biophytis
N/A$1.45
flat
N/A-78.6%$509KN/A0.0030
VRPX
Virpax Pharmaceuticals
1.5872 of 5 stars
$0.39
+0.3%
$75.00
+19,130.8%
-98.8%$484KN/A0.007Gap Down
KRBP
Kiromic BioPharma
N/AN/AN/AN/A$330KN/A-0.0660Gap Down
High Trading Volume
NCNA
NuCana
2.5297 of 5 stars
$0.05
+3.6%
$25.00
+48,255.9%
-98.0%$311KN/A-0.0130Gap Up
TFFP
TFF Pharmaceuticals
N/A$0.07
flat
N/AN/A$289K$730K-0.0119
MYMD
MyMD Pharmaceuticals
N/A$0.12
+2.1%
N/A-93.3%$280KN/A0.006Gap Down
High Trading Volume
TCBP
TC Biopharm
N/A$0.68
-55.8%
$48.00
+6,948.5%
-99.5%$279K$4.76M0.0080High Trading Volume
BON
Bon Natural Life
1.1387 of 5 stars
$1.41
+0.7%
N/AN/A$240K$23.84M0.00100
VINC
Vincerx Pharma
3.0335 of 5 stars
$0.04
+15.2%
$40.00
+91,016.2%
-99.7%$230KN/A0.0060News Coverage

Related Companies and Tools


This page (NASDAQ:SPRC) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners